BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $566 From $500

Vertex Pharmaceuticals (VRTX) has an average outperform rating and a price target range of $325 to $589, according to analysts polled by Capital IQ.Price: 490.21, Change: +2.09, Percent Change: +0.43

MT NewswiresJul 19 09:17 ET

Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow JonesJul 19 07:12 ET

Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.

Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.

Dow JonesJul 19 07:12 ET

Vertex Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 2.43% HC Wainwright & Co. $462 → $500 Maintains Buy 07/11/2024 -6.79% Morgan Stanley $402 → $45

BenzingaJul 19 06:59 ET

H.C. Wainwright Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500

H.C. Wainwright analyst Andrew Fein maintains $Vertex Pharmaceuticals(VRTX.US)$ with a buy rating, and adjusts the target price from $462 to $500.According to TipRanks data, the analyst has a

Moomoo NewsJul 19 06:34 ET · Ratings

Express News | Vertex Pharmaceuticals Inc. : H.c. Wainwright Raises Target Price to $500 From $462

ReutersJul 19 06:06 ET